Enveric Biosciences, Inc. (ENVB)
NASDAQ: ENVB · Real-Time Price · USD
1.440
+0.050 (3.60%)
Oct 20, 2026, 4:00 PM EDT - Market closed
Enveric Biosciences Employees
As of December 31, 2025, Enveric Biosciences had 6 total employees, including 5 full-time and 1 part-time employees. The number of employees did not change compared to the previous year. That makes Enveric Biosciences the 41,345th largest employer in the world and 6,367th in the United States.
Employees
6
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,014,755
Market Cap
6.45M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 6 | 0 | - | 5 | 1 |
| Dec 31, 2024 | 6 | -1 | -14.29% | 5 | 1 |
| Dec 31, 2023 | 7 | -19 | -73.08% | 7 | 0 |
| Dec 31, 2022 | 26 | 2 | 8.33% | 25 | 1 |
| Dec 31, 2021 | 24 | 21 | 700.00% | 23 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Evogene | 52 |
| Moleculin Biotech | 17 |
| FibroBiologics | 15 |
| Processa Pharmaceuticals | 12 |
| CNS Pharmaceuticals | 8 |
| Alzamend Neuro | 6 |
| XTL Biopharmaceuticals | 5 |
| Can-Fite BioPharma | 5 |
ENVB News
- 5 weeks ago - Enveric receives Notice of Allowance from USPTO for application for EVM401 - TheFly
- 5 weeks ago - Enveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series - Business Wire
- 7 weeks ago - Enveric Biosciences to Present at H.C. Wainwright 28th Annual Global Investment Conference - Business Wire
- 2 months ago - Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026 - Business Wire
- 2 months ago - Enveric Biosciences reports new preclinical data on EB-003 - TheFly
- 2 months ago - Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003 - Business Wire
- 2 months ago - Enveric ‘welcomes’ final FDA guidance for psychedelic drug development - TheFly
- 2 months ago - Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development - Business Wire